Synopsis
This meeting aims to provide practical insights into some of the recent improvements in this key area. It follows on from the success of the 'Designing Safer Medicines' meeting in 2011.
There is a clear need in drug development to reduce attrition from clinical studies especially due to toxicology. It was estimated that a 5-10% improvement in the attrition rate could double the output of marketed drugs and various preclinical approaches and strategies have been developed to help the chemist design safer medicines.
Attendees
This meeting is targeted at all those who are involved in the lead identification and lead optimisation processes in Drug Discovery and those interested in furthering their knowledge of current and emerging approaches to designing better toxicology models and safer Drug Candidates.
Programme
Day 1
- 09:30
- Registration and refreshments
- 09:55
- Welcome and introduction
- 10:00
- Reducing cardiovascular safety-related attrition: the good, the bad, the ugly and the future
Dr Chris Pollard, AstraZeneca
- 10:40
- Screening strategies for Drug-Induced Liver Injury
Dr James Sidaway, Independant
- 11:20
- In vivo models in safety and toxicity: cross-company data sharing to assess what works and what doesn't
Dr Kathryn Chapman, NC3Rs
- 12:00
- Lunch and exhibition
- 13:30
- Investigative approaches to address toxicological issues in drug discovery and development: case examples
Dr Monicah Otieno, Bristol-Myers Squibb
- 14:10
- Designing in safer chemistry space; the use of multiparametric models in predicting drug safety
Dr Nigel Greene, Pfizer Worldwide Medicinal Chemistry
- 14:50
- Early safety evaluation: combining polypharmacology predictions and network biology to prioritize experimental testing
Dr Cedric Merlot, LeadOp Computing
- 15:15
- Refreshments
- 15:45
- Big data analysis - application for designing safer drugs
Dr Edward J Griffen, MedChemica Ltd
- 16:10
- Improving toxicity predictions to design safer acidic molecules
Dr Nigel Swain, Pfizer Worldwide Medicinal Chemistry
- 16:35
- Influence of early safety science in drug discovery
Dr Mark Anderton, AstraZeneca
- 17:00
- Closing remarks
- 17:10
- Wine reception
Accessibility Grants
SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.
Venue and Contact
Fees
Early Bird Rate - before 29 August 2014
One-Day Fee |
|
Two-Day Fee* |
|
SCI Member |
GB£100 |
SCI Member |
GB£175 |
SCI Student Member |
GB£35 |
SCI Student Member |
GB£60 |
Non-Member |
GB£130 |
Non-Member |
GB£235 |
Standard Rate - after 29 August 2014
One-Day Fee |
|
Two-Day Fee* |
|
SCI Member |
GB£115 |
SCI Member |
GB£205 |
SCI Student Member |
GB£40 |
SCI Student Member |
GB£70 |
Non-Member |
GB£150 |
Non-Member |
GB£270
|
Become an SCI Member and save on this and future events
See Membership Options
Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
For booking terms and conditions click here.
CPD Info
SCI Members attending this meeting are able to claim CPD points.
Additional Info
Further Information and Sponsorship Opportunities
Discounts are available for dual registration with the 'Highlights in Medicinal Chemistry' meeting which will be run back-to-back with this meeting.
For further information about sponsorship opportunities, please contact the conference team using the details provided below.